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Abstract: Serotonin receptors (5-HTRs), especially the 5-HT1A subtype, have been
the subject of intensive research for the past decade, due to their function in human
physiology. Several structurally different classes of ligands are known to bind to the
5-HT1A receptor, but arylpiperazine derivatives are among the most important lig-
ands. In the work, docking analyses were used to explain the binding affinities of a
series of ligands with different N-1 substituent. All ligands had in common the
arylpiperazine structure, while the N-1 substituent was modified to investigate the
influence of ligand structure on its binding affinity. The shape and size, as well as the
rigidity of the substituents were altered to investigate the possible effects on the for-
mation of the receptor – ligand complex.
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INTRODUCTION
G protein-coupled receptors (GPCRs) comprise not only the largest superfamily
of proteins in the body, with more than 1000 different proteins described as GPCRs,
but also the most interesting target for protein targeting pharmaceuticals. Serotonin re-
ceptors (5-HTRs) have been the subject of intensive research in the past decade be-
cause of their function in human physiology.1 To date, seven classes, including 14 sub-
types, of 5-HTR, have been found, and only one subtype, 5-HT3, does not belong to
GPCRs. Among these transmembrane serotonin receptors, the 5-HT1A subtype is the
best studied. Several structurally different classes of ligands are known to bind to this
receptor2 and arylpiperazine derivatives are among the most important 5-HT1A lig-
ands. The main obstacle to research in this field is the fact that, despite the intensive re-
search, the 3D structure and mechanism of action of GPCRs are still not known.
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The great drawback for arylpiperazine derivatives as potential pharmacologi-
cally usable ligands for the 5-HT1A receptor is that they are not sufficiently selective.
Many of them show a tendency to bind strongly to other 5-HTR subtypes as well as
to other GPCRs (D2, adrenergic...). Knowledge about the details of the binding pro-
cess of the ligand to the 5-HT1A binding site would be helpful for designing ligands
with a satisfactory selectivity to fulfill the pharmacological demands.
The binding of small molecules with the arylpiperazine moiety to the active site
of the 5-HT1A receptor was the object of various studies and investigations, resulting
in several reasonable suggestions for the binding mechanism,3,4 but no unified the-
ory was postulated for arylpiperazine derivatives with a high affinity for 5-HT1A.
The main goal of this work was to shed additional light on the influence of the N-1
substituent of N-arylpiperazines on the binding process of these ligands. A series of
ligands having in common the arylpiperazine structure but with different N-1 sub-
stituents ("head" part) varying in shape, size and rigidity was used in order to investi-
gate their possible effects on the formation of the receptor – ligand complex.
EXPERIMENTAL
The model of the 5-HT1A receptor was built by comparative modeling using the MODELLER
program,5 which is a part of the InsightII software6 and the binding site of that model determined as
described in an earlier paper.7 The amino acids forming the binding site of the 5-HT1A model are
listed in Table I. The position of the key amino acids in this binding site can be seen in Fig. 1. The
binding site designed in this way corresponds well to the rather conserved binding domain of rho-
dopsin-like receptors between helices III, V, VI and VII of Class A transmembrane receptors.8 Some
of the listed amino acids were earlier identified by point mutations to have key interactions with dif-
ferent types of ligands.9,10 The proposed binding site includes well-defined, conserved amino acid
residues and amino acid residues found by computer analysis of the 5-HT1A receptor model.
TABLE I. Amino acids in the proposed binding site of the 5-HT1A model
Amino acids in
TM3 e2 TM5 TM6 TM7
Phe 112 (3.28) Asp 185 Tyr 195 (5.38) Cys 357 (6.47) IIe 385 (7.38)
IIe 113 (3.29) Ala 186 Thr 196 (5.39) Trp 358 (6.48) Asn 386 (7.39)
Ala 114 (3.30) Cys 187 Ser 199 (5.42) Leu 359 (6.49) Trp 387 (7.40)
Asp 116 (3.32) Thr 188 Thr 200 (5.43) Pro 360 (6.50) Leu 388 (7.41)
Val 117 (3.33) IIe 189 Gly 202 (5.45) Phe 361 (6.51) Gly 389 (7.42)
Leu 118 (3.34) Ala 203 (5.46) Phe 362 (6.52) Tyr 390 (7.43)
Cys 119 (3.35) Phe 204 (5.47) Ser 391 (7.44)
Cys 120 (3.36) Asn 392 (7.45)
Thr 121 (3.37)
Although several of envisaged 5-HT1A models exist today,
11,12 they are usually models without
loops, because there is almost no information about the spatial arrangement of amino acids in the
loops. However, one important fact is known, i.e., that there is a conserved disulfide bond connecting
Cys 109 (C 3.25)13 on TM3 and Cys 187, amino acid from the e2 loop.14 In an earlier paper, the possi-
ble importance of the e2 loop in modeling receptor – ligand interactions7 was highlighted, especially
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of Thr 188, situated near the conserved region in that loop (Cys 109 – Cys 187), which is capable of
forming a hydrogen bond with a convenient substitutent on the arylpiperazine part of the ligand.
TABLE II. Structures and activities of the investigated ligands
Ligand X R Ki/nM
1 –OCH3 0.02
19
2 –OCH3 79.6
19
3 –OCH3 1.3
20
4 –OCH3 0.4
21
5 –OCH3 8.0
22
6 –H 10.123
7 –H 2.823
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Fig. 1. The binding site of the 5-HT1A re-
ceptor model.
Ligand X R Ki/nM
8 –H 70.723
9 –H 4.223
All ligands used in the docking analysis were modeled using the Accelrys InsightII program
Build module. The initial geometry was optimized until energy minima were reached. The geometry
obtained in this manner was the starting point for the docking analysis and the conformation of the
arylpiperazine part corresponds to the conformations of the X-ray structures of the arylpiperazines
deposited in the Cambridge Structural Database (CSD).15 This conformation did not change during
the calculations.
Ligand docking of the ligands in Table II was done by simulated annealing using the Affinity
module from InsightII on SGI Octane2 workstation.16 All ligands were docked as protonated, using
the CFF91 force field. The charges of the amino acid residues were adjusted as required. The protein
bind site was determined by combining the results from experimental data and the InsightII bind site
analysis module. The initial position of the ligand in the bind site was arbitrary in respect of the
arylpiperazine part facing TM6 and TM7, while the protonated nitrogen on the piperazine part was
kept in close proximity to Asp 116. After the initial ligand placement, no further constrains were ap-
plied and a docking procedure based on the Monte Carlo methodology was carried out. Up to 100
structures were produced in every run and each was finally optimized in order to remove steric inter-
action with a gradient limit of 0.0042 kJ/mol or 4000 optimization steps.
The obtained docked structures were examined, and those with the lowest total energy were further
filtered to obtain docking structures with the best ligand fit. The structures were selected based on the
following criteria: lowest total energy of the complex, shortest salt bridge formed between Asp 116 and
the proton on the piperazine ring nitrogen, conformation of the arylpiperazine ring analogous to the crys-
tal structure15 and the aryl part of the molecule positioned in the rear hydrophobic pocket of the ligand.
After an initial criterion was satisfied, the second step was an examination of the different interactions
that could be formed between the receptor and the front part of the ligand. In this way, the best possible
docking structures were selected. The structures were rendered using PovRay raytracer v3.6.17
RESULTS AND DISCUSSION
At present, it is well known that for the binding of ligands with an arylpi-
perazine moiety the formation of a salt bridge between the protonated N-1 nitrogen
of arylpiperazine and the negatively charged Asp 116 is required. This interaction
guides the ligand towards its binding site, most probably by zipper-like mecha-
nisms,18 leading to interactions with key residues in the receptor binding site. For
1,4-disubstituted arylpiperazines, hydrophobic and/or H-bonding interactions of
the 4-N-aryl substituent with amino acid residues from TM6, TM7 and e2 also play
an important role both in the binding affinity as well as in the correct positioning of
the entire ligand in the binding site. After these interactions are established, the rest
of the molecule is placed in the best possible position, accomplishing the position
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TABLE II. Continued
and conformation that will provide the optimal energy stabilization and the least
steric and torsional strain.
The results of the docking analysis show that all the investigated ligands bind
in a similar manner. A short salt bridge between Asp 116 and a protonated nitrogen
atom is present, which is a precondition for good binding affinity. All the ligands
form an aromatic–aromatic interaction between the arylpiperazine part and Phe
361 (F 6.51) and Tyr 390 (Y 7.43). In addition, the ligands 1 – 5 can form a hydro-
gen bond between their methoxy group on the aryl ring and Thr 188 in the e2 loop
of the receptor, as described earlier.7
Binding of the head part of the ligand is influenced by its shape, size and
chemical character (aromatic or aliphatic moiety, capability of forming hydrogen
bonds, presence of heteroatom in the aromatic ring, etc.).
Docking analysis of ligand 1 (Fig. 2) shows all the features mentioned above.
A short salt bridge between Asp 116 and a protonated nitrogen is present as well as
two edge-to-face (ETF) interactions together with a hydrogen bond positioned
beteeen the methoxy group located on the arylpiperazine part and Thr 188. The
head section of the ligand, arylcyclohexyl part, forms a hydrogen bond connecting
its methoxy group and Thr 200 (T 5.43), together with several CH –  interactions
with Phe 204 (F 5.47) and Phe 362 (F 6.52). All those interactions, combined with
the ligand shape and size (distance between arylpiperazine part and arylcyclohexyl
part) and the rigidity of the ligand structure, lead to the highest activity toward the
5-HT1A receptor in the investigated group (Table II).
Ligand 2 (Fig. 3) is the cis isomer of the ligand 1. Docking analysis shows that
the cis isomer cannot form a hydrogen bond with Thr 200, nor CH –  interactions,
because of a significant difference in shape compared with the trans isomer, ligand
1. This isomer is positioned in a different part of the binding site, in the cavity near
the top of the 5-HT1A binding site, faced toward the extracellular space. The only
significant interaction this ligand can make is a hydrogen bond with Ser 200 (S
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Fig. 2. Ligand 1 docked in the
active site.
Fig. 3. Ligand 2 docked in the
active site.
5.42), but this bonding would lead to a weakening of the hydrogen bond with Thr
188, losing the favorable position for ETF interactions of the aryl group and, possi-
bly, even to an extension of the salt bridge between the ligand and Asp 116. One of
such structures is shown in Fig. 3. This is not an effective position for binding and
ligand 2 shows low affinity toward 5-HT1A.
Analysis of the best docked structure of the ligand 3 (Fig. 4) shows that a
somewhat shorter N-1 substituent of the ligand (N-ethylbenzamide) cannot form a
hydrogen bond with Thr 200, but there is a possibility of a slightly weaker hydro-
gen bonding with Trp 358 (W 6.48). This interaction, together with the aro-
matic–aromatic interactions between the benzamide part of the ligand and Phe 204
and Phe 362, leads to a lower binding to 5-HT1A when compared with 1.
Ligand 4 (Fig. 5) is characterized by a longer alkyl chain and the bulky ada-
mantyl group, instead of an aromatic moiety present in the other ligands. Docking
analysis shows that the longer alkyl chain can be coiled inside the binding site,
pushing the adamantylamide part toward Phe 204, Phe 362 and Leu 359, thus hid-
ing the lipophilic adamantyl group deep inside the hydrophobic pocket formed by
these amino acid residues. An additional hydrogen bond is formed with Ser 199,
leading to a high 5-HT1A affinity. Although the hydrogen bond with Thr 188 is lon-
ger (and weaker), the position of the aromatic hydrogens in this aryl group, unlike
in ligand 2, still enables the formation of good ETF interactions.
Ligand 5 (Fig. 6) represents a somewhat larger group in the head part; the
2-cyclohexylisoindoline-1,3-dione group cannot form hydrogen bonds with either
Ser 199 or Thr 200, but it can form weak bonding with the hydrogen from the pep-
tide bond between Phe 362 and Phe 361. Docking analysis shows that the iso-
indoline group can fit between Phe 204 and Phe 362, forming aromatic–aromatic
interactions, thus stabilizing the receptor–ligand complex. This ligand exhibits
moderate binding affinity.
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Fig. 4. Ligand 3 docked in the
active site
Fig. 5. Ligand 4 docked in the
active site
Ligands 6 to 9 cannot form an additional bond in the arylpiperazine part, being
without the 2-methoxy substituent. They also share a common 6-ethyl-1H-be -
nzodimidazole moiety, linked to the arylpiperazine part.
Docking analysis of ligand 6 (Fig. 7) shows the formation of the following inter-
actions: a short salt bridge between Asp 116 and the protonated nitrogen atom of the
piperazine part of the ligand, ETF interactions between the arylpiperazine part and
Phe 361 and Tyr 390. The head section of the ligand can form additional aro-
matic–aromatic and hydrophobic interactions, via the 2-phenyl substituent of the
benzodimidazole part and Phe 204, Phe 362 and Leu 359. Docking analysis shows
that aromatic–aromatic interactions in this part can be -stacking interactions due to
the distance and orientation of the aromatic rings. This ligand cannot form hydrogen
bonds with the receptor, therefore its binding affinity is weak or moderate.
Ligands 7 and 8 (Figs. 8 and 9) are similar in structure, with a pyridinyl substi-
tuent in the benzodimidazole part. Docking analysis of ligand 7 shows the presence
of an intramolecular hydrogen bond between the nitrogen atom in the pyridine and
the proton on the nitrogen atom in the benzimidazole ring. Thus the structure of
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Fig. 6. Ligand 5 docked in the
active site.
Fig. 7. Ligand 6 docked in the
active site.
Fig. 8. Ligand 7 docked in the
active site.
Fig. 9. Ligand 8 docked in the
active site.
ligand 7 is far more rigid than those of ligands 6 and 8. Ligand 7 is stabilized by aro-
matic–aromatic and hydrophobic interactions with Phe 204, Phe 362 and Leu 359.
Due to its inflexibility and the position of the nitrogen atom in the pyridine ring in
position 2 with respect to the rest of the molecule, the affinity toward the 5-HT1A re-
ceptor is moderate but, nevertheless, slightly higher than for ligand 6.
Ligand 8 has a nitrogen atom in position 3 to the benzodimidazole moiety.
Experimental data show a low binding affinity toward the 5-HT1A receptor. A first
glance at the docking structures shows that there are no major differences in the
general position of ligands 7 and 8 in the binding site, but there is a significant de-
crease in affinity. This can be explained if different orientations of pyridine ring are
considered. This part of the ligand is responsible for stabilizing aromatic–aromatic
and hydrophobic interactions with Phe 204, Phe 362 and Leu 359, but the position
and electrostatic properties of the nitrogen atom, together with, to some extent, a
less restricted rotation of this part of the molecule than in ligand 7, lead to an unfa-
vorable orientation and position for -stacking bonding interactions.
The benzodimidazole part of ligand 9 (Fig. 10) has a bulky diphenylmethyl
substituent. Although it is a large and rotationally restricted group, docking analy-
sis shows that it can still be docked inside the 5-HT1A receptor. One phenyl ring in
the diphenylmethyl group can easily fit between Phe 204 and Phe 362, while the
other is located in a binding cavity facing the extracellular space, similar to the
space occupied by ligand 2. Stabilization of the receptor–ligand complex is
achieved by aromatic–aromatic and hydrophobic interactions. Since rigid struc-
tures are more favorable than flexible ones, the binding affinity is moderate and
comparable to ligands 6 and 7.
CONCLUSION
Docking analysis showed that all the investigated ligands bind in a similar
manner. The first step in the ligand binding is the formation of a short salt bridge
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Fig. 10. Ligand 9 docked in the
active site.
between the negatively charged oxygen atoms on Asp 116 and a positively charged
nitrogen atom in the piperazine part of the ligand. This is followed by the formation
of an aromatic–aromatic interaction (edge-to-face type) between the arylpipera-
zine part of the ligand and the rear hydrophobic pocket of the receptor, formed by
Phe 361 and Tyr 390 on the TM6 and TM7 helices, respectively. An additional hy-
drogen bond can be formed with Thr 188 located in the e2 loop, closing the pocket
on the extracellular side. For binding ligands with an arylpiperazine moiety, these
interactions are crucial.7,24
Careful comparison of the docking analysis results shows the existence of an-
other hydrophobic pocket, located between TM5 and TM6, in the front part of the
5-HT1A receptor, formed by Phe 204 on TM5, as well as Phe 362 and Leu 359 on
TM6. Ligands 1 and 3– 9, in their binding to the 5-HT1A receptor, form as least one
aromatic–aromatic interaction with these amino acid residues.
In case of ligands 1, 3 and 4, the binding affinity is influenced by the formation
of hydrogen bonds with Thr 200, Trp 358 or Ser 199, respectively, while ligands 5
– 9 cannot form these hydrogen bonds and their affinity depends only on the num-
ber and strength of aromatic–aromatic and hydrophobic interactions.
The importance of the formation of hydrogen bonds between a ligand and Ser
199 and/or Thr 200 was investigated earlier,25 but since many ligands with a mod-
erate to high affinity cannot form this type of interactions, it can be concluded that
they are not a decisive factor in the formation of the receptor–ligand complex.
The results of docking analysis show that the front hydrophobic pocket can ac-
commodate both aromatic and aliphatic substituents, ranging from the methoxy
group (ligand 1) up to the adamantyl group (ligand 4). This finding shows that the
parts of TM5 and TM6 near the extracellular side of the protein are to some extent
flexible and can adjust their conformation during ligand binding. In support of this,
the experimental results show that ligands with rigid structures (7 and 9) possess
higher affinity than similar flexible ligands (6 and 8).
In case of aromatic substituents, docking analysis shows that the preferable
orientation of the Phe 204 and Phe 362 residues and the aromatic part of the ligand
is a stacked one (sandwich) but exact orientation (parallel, displaced or paral-
lel-displaced) cannot be asserted by docking analysis alone. The introduction of a
heteroatom in the aromatic part of the ligand (as in ligands 7 and 8) shows mixed
influence on the binding affinity. While a nitrogen in position 2 of the aromatic
ring leads to an increase in the binding affinity, a nitrogen in position 3 causes a
large decrease compared to ligand 6. A possible explanation lies both in the rigidity
of the system (ligand 7 is more rigid than 6 and 8), as well as a charge distribution
which can affect the formation of aromatic–aromatic interactions.
Comparing the ligand afinity, it can be concluded that ligands 1, 3 and 4, capa-
ble of forming hydrogen bonds, show a somewhat higher affinity than the other in-
vestigated ligands. A rigid structure is preferable to a flexible one, because it facili-
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tates the formation of a hydrogen bond, by placing corresponding functional
groups in close proximity. Ligands which form only aromatic–aromatic interac-
tions with the receptor bind with a moderate affinity. The binding affinity of the
ligands 5–9 is determined by the strength of the interactions formed between the
ligand and amino acid residues in the front hydrophobic pocket. In these ligands, a
rigid structure is also preferable and results in higher ligand affinity.
To shed some more light on ligand binding to the 5-HT1A receptor, regarding
the postulated front hydrophobic pocket, a large training set, comprised of a num-
ber of different ligands sharing a common arylpiperazine moiety and an aromatic
or aliphatic head segment, with or without a heteroatom, is currently being built. In
this way, it is hoped a clearer picture regarding interactions leading to the stabili-
zation of the receptor–ligand complex can be obtained.
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Serotoninski receptori su, a naro~ito 5-HT1A podtip, zbog zna~ajne uloge u fi-
ziologiji qudskog organizma, predmet intenzivnog izu~avawa tokom protekle dece-
nije. Poznato je da se za 5-HT1A receptor vezuje nekoliko strukturno razli~itih klasa
liganada, ali su arilpiperazinski derivati me|u najzna~ajnijim. Da bi objasnili
vezivawe serije liganada sa razli~itim N-1 supstituentima za receptor koristili
smo analizu vezivawa (docking analizu). Svi ligandi su imali zajedni~ku arilpipera-
zinsku strukturu dok su im N-1 supstituenti modifikovani tako {to je mewan oblik,
veli~ina kao i krutost supstituenta da bi se istra`io wihov eventualni uticaj na
formirawe kompleksa receptor – ligand.
(Primqeno 19. maja, revidirano 24. jula 2006)
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